KPTXEarnings•prnewswire•
Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress
Sentiment:Positive (65)
Summary
– New Patient Screening for Phase 3 SENTRY Trial in Myelofibrosis Expected to Close This Week; Top-Line Results Anticipated in March 2026 – – Total Revenue was $37.9 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $29.7 Million, up 6% compared to Second Quarter of 2024 – –...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 11, 2025 by prnewswire